Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequencing Regorafenib and Trifluridine/Tipiracil in mCRC
NCT04450836Phase 2Terminated
- Sponsor
- Unicancer
- Start
- Nov 2020
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of regorafenib and trifluridine + tipiracil in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Unicancer. Primary endpoint: Feasibility of treatment sequence (R-TT or TT-R) at 5 months. Started Nov 2020; status: terminated.
02
Drugs
regorafenibtrifluridine + tipiracil
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04450836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04450836.